Literature DB >> 11692977

Atypical antipsychotic use in treating adolescents and young adults with developmental disabilities.

R Friedlander1, S Lazar, J Klancnik.   

Abstract

OBJECTIVE: To study the usage, efficacy, and side effects patterns of atypical neuroleptics (atypicals) in adolescents and young adults with developmental disabilities (DDs) (mental retardation).
METHOD: We undertook a chart review of adolescents and young adults (under age 25 years) seen by our specialized mental health team.
RESULTS: Risperidone and olanzapine were by far the most frequently prescribed atypicals. Robust clinical effects were noted for both psychotic and nonpsychotic disorders. Most patients tolerated atypicals well, although a significant minority did experience neuroleptic induced movement disorders (NIMDs), particularly dystonias and dyskinesias. Female patients with DDs appear to be at particular risk of NIMDs.
CONCLUSIONS: Atypicals are useful in treating various conditions associated with DDs. This population, however, seems particularly sensitive to NIMDs, hence caution and close monitoring are required.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11692977     DOI: 10.1177/070674370104600807

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  3 in total

1.  Low-Dose Risperidone-Induced Oculogyric Crises in an Adolescent Male with Autism, Tourette's and Developmental Delay.

Authors:  Tamara Masliyah; Yasser Ad-Dab'bagh
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2011-08

2.  Harms of Antipsychotics in Children and Young Adults: A Systematic Review Update.

Authors:  Jennifer Pillay; Khrista Boylan; Amanda Newton; Lisa Hartling; Ben Vandermeer; Megan Nuspl; Tara MacGregor; Robin Featherstone; Normand Carrey
Journal:  Can J Psychiatry       Date:  2018-06-04       Impact factor: 4.356

Review 3.  Clozapine for psychotic disorders in adults with intellectual disabilities.

Authors:  Muhammad Ayub; Khalid Saeed; Tariq A Munshi; Farooq Naeem
Journal:  Cochrane Database Syst Rev       Date:  2015-09-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.